Latest Shareholder Support News

Iceni Gold has upsized its recent placement to nearly $1.76 million, securing additional funds to advance drilling and exploration at its flagship 14 Mile Well Gold Project in Western Australia.

Electrum Discovery Corp. shareholders have overwhelmingly approved a merger with MinRex Resources, setting the stage for a significant cross-continental consolidation in gold and base metals exploration.

WA Kaolin Limited has announced a $34.9 million recapitalisation plan involving a non-renounceable entitlement issue and debt conversion to strengthen its balance sheet and fund operational improvements at its Wickepin kaolin project.

Genesis Energy has successfully completed a NZ$300 million rights offer, with strong shareholder participation including the Crown maintaining its majority stake. The capital raise underpins the company’s Gen35 strategy and sets the stage for upcoming share trading.

Regener8 Resources has announced a $2.03 million entitlement offer at a 41% discount, aiming to accelerate exploration and acquisition of its Srebrenica North Project. Eligible shareholders can subscribe at one new share for every two held, positioning the company for its next growth phase.

Shriro Holdings Limited has announced a $15 million off-market share buy-back at $0.81 per share, representing nearly 26% of its issued capital. The move aims to return excess capital to shareholders while supporting the company’s capital-light growth model.

HighCom Limited has successfully raised nearly $800,000 through a Share Purchase Plan, adding to a prior $7 million placement to fund product upgrades and sales growth.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

Eden Innovations Ltd reports a $1.43 million half-year profit, reversing prior losses thanks to a $4.45 million property sale and significant debt reduction, while advancing international commercialisation of its concrete and fuel technologies.

Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

Actinogen Medical has successfully completed a $16.8 million capital raising, combining a $12 million placement with a $4.8 million share purchase plan, to fund its pivotal Alzheimer’s disease trial and other 2026 initiatives.